Results 1 to 10 of about 3,103 (173)

Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort [PDF]

Journal of the International AIDS Society
Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history.
Jara Llenas‐García, María del Mar Arcos Rueda, Ruth Calderón Hernaiz, Roberto Pedrero Tomé, Otilia Bisbal Pardo, Mariano Matarranz, Miguel Torralba, María José Galindo Puerto, Adrián Rodríguez, María Peñaranda Vera, Isabel Sanjoaquín Conde, Sara de laFuente Moral, Alfonso Cabello‑Úbeda, Carolina Navarro San Francisco, Karenina Antelo Cuéllar, Marc Pedrosa Aragón, María Aguilera García, Juan Tiraboschi, Rosa María Martínez Álvarez, María Jesús Vivancos, Carmen Montero Hernández, Enrique Bernal Morell, Noemí Cabello‐Clotet, Luis Enrique Morano Amado, Laura Gisbert Pérez, María Antonia Sepúlveda, María Remedios Alemán Valls, Antonio Jesús Sánchez Guirao, Chiara Fanciulli, Cristina Escrig, Eva María Ferreira Pasos, Ana Lucas‐Dato, Sara García Torras, Carmen Hidalgo Tenorio, Miriam Estébanez, Magdalena Muelas‑Fernandez, Juan Emilio Losa García, Ana Cerezales Calviño, María Elisa Pino Díaz, Clara Martínez Montes, Víctor Arenas García, Francisco Arnaiz de las Revillas, Hadrián Pernas Pardavila, Sergio Padilla, María Ángeles Garcinuño Jiménez, Lucía Alonso Alonso, Noemí Ramos Vicente, Patricia Noemí Barragán Gallo, Rebeca Cabo Magadan, Míkel delÁlamo, Miguel Vicente Egido Murciano, Alberto Juárez Toquero, Alberto Romero Palacios, Marta Clavero Olmos, María del Mar García Navarro, José Sanz, Juan Carlos Gainzarain, Marta Milian Sanz, Beatriz de laCalle, Oscar Luis Ferrero Benéitez, Jesús Troya, Luis Buzón‐Martín, The RELATIVITY Group   +62 more
doaj   +3 more sources

Design and Testing of a Cabotegravir Implant for HIV Prevention

Journal of Controlled Release, 2021
Long-acting antiretroviral implants could help protect high-risk individuals from HIV infection. We describe the design and testing of a long-acting reservoir subcutaneous implant capable of releasing cabotegravir for several months. We compressed cabotegravir and excipients into cylindrical pellets and heat-sealed them in tubing composed of ...
Dipu Karunakaran, Ronald S Veazey, Thomas J Hope   +2 more
exaly   +4 more sources

Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities [PDF]

Journal of the International AIDS Society
Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage.
Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov   +11 more
doaj   +2 more sources

Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients [PDF]

Microorganisms
Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) have been incorporated into the treatment of people living with HIV (PLWH), but evidence on their metabolic impact in real-world settings remains limited.
Marta Segura Díaz, Antonio Collado Romacho, Sergio Ferra Murcia   +2 more
doaj   +2 more sources

Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States [PDF]

Journal of the International AIDS Society
Introduction Long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) represents a breakthrough in HIV treatment. However, understanding how to optimize real‐world service delivery and user experiences among people with HIV (PWH) remains limited ...
Xavier A. Erguera, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Jon Oskarsson, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester, Katerina A. Christopoulos   +17 more
doaj   +2 more sources

Real-life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine in HIV-infected individuals [PDF]

Infectious Diseases and Tropical Medicine, 2023
OBJECTIVE: Switching from oral anti-retroviral therapy (ART) to intramuscular administration of Cabotegravir-Rilpivirine (CAB+RPV) has been observed to decrease the number of pills that patients need to take, enhance patient satisfaction, and promote ...
S. Spampinato, A. Saia, Y. Russotto, C. Micali, A. Marino, M. Ceccarelli, E. Venanzi Rullo, G. Pellicanò, G. Nunnari   +8 more
doaj   +1 more source

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans

Pharmaceutics, 2023
Microarray patches (MAPs) are currently under investigation as a self-administered, pain-free alternative used to achieve long-acting (LA) drug delivery.
Hannah Kinvig, Rajith K. R. Rajoli, Henry Pertinez, Lalitkumar K. Vora, Fabiana Volpe-Zanutto, Ryan F. Donnelly, Steve Rannard, Charles Flexner, Marco Siccardi, Andrew Owen   +9 more
doaj   +1 more source

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model

Pharmaceutics, 2022
Animal pregnancy models can be useful tools to study HIV antiretroviral safety and toxicity and to perform mechanistic studies that are not easily performed in humans.
Haneesha Mohan, Kieran Atkinson, Birgit Watson, Chanson J. Brumme, Lena Serghides   +4 more
doaj   +1 more source

Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR

Future Journal of Pharmaceutical Sciences, 2021
Background Using a Symmetry C18 (4.6 × 150 mm, 3.5) column, a high-performance liquid chromatographic method for quantification of Rilpivirine and Cabotegravir in active pharmaceutical ingredients was developed and validated.
Anuradha Vejendla, Subrahmanyam Talari, Raju Moturu, S. N. Murthy Boddapati, A. Emmanuel Kola   +4 more
doaj   +1 more source

Three-step synthetic procedure to prepare dolutegravir, cabotegravir, and bictegravir

Green Chemistry Letters and Reviews, 2022
Dolutegravir, cabotegravir, and bictegravir are three integrase inhibitors, which were used for HIV-1 in the clinic. In this paper, a continuous three-step synthetic strategy was developed to prepare dolutegravir, cabotegravir, and bictegravir in a ...
Xianheng Wang, Song Chen, Hanqi Cui, Yuqi He, Changkuo Zhao   +4 more
doaj   +1 more source